<SEC-DOCUMENT>0001437749-22-027045.txt : 20221114
<SEC-HEADER>0001437749-22-027045.hdr.sgml : 20221114
<ACCEPTANCE-DATETIME>20221114074143
ACCESSION NUMBER:		0001437749-22-027045
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20221114
DATE AS OF CHANGE:		20221114

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Diffusion Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001053691
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				300645032
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37942
		FILM NUMBER:		221380317

	BUSINESS ADDRESS:	
		STREET 1:		300 EAST MAIN STREET
		STREET 2:		SUITE 201
		CITY:			CHARLOTTESVILLE
		STATE:			VA
		ZIP:			22902
		BUSINESS PHONE:		(434) 220-0718

	MAIL ADDRESS:	
		STREET 1:		300 EAST MAIN STREET
		STREET 2:		SUITE 201
		CITY:			CHARLOTTESVILLE
		STATE:			VA
		ZIP:			22902

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RestorGenex Corp
		DATE OF NAME CHANGE:	20140307

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Stratus Media Group, Inc
		DATE OF NAME CHANGE:	20080722

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FERIS INTERNATIONAL, INC.
		DATE OF NAME CHANGE:	20080228
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>dffn20221113_defa14a.htm
<DESCRIPTION>FORM DEFA14A
<TEXT>
<html><head>
	<title>dffn20221113_defa14a.htm</title>

	<!-- Generated by ThunderDome Portal - 11/14/2022 3:24:10 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0">
<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0">
<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;"><b>UNITED STATES</b></p>

<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Washington, D.C. 20549</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 18pt; font-variant: normal; margin: 0pt; text-align: center;"><b>FORM 8-K</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CURRENT REPORT</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Pursuant to Section 13 or 15(d) of</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>the Securities Exchange Act of 1934</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Date of Report (Date of earliest event reported): November 13, 2022</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto">
<p style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt;"><b>DIFFUSION PHARMACEUTICALS INC.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 33.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Delaware</b></p>
			</td>
			<td style="vertical-align: top; width: 33.7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>000-24477</b></p>
			</td>
			<td style="vertical-align: top; width: 33.7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>30-0645032</b></p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 33.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">(State or other jurisdiction of incorporation)</p>
			</td>
			<td style="vertical-align: top; width: 33.7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">(Commission File</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Number)</p>
			</td>
			<td style="vertical-align: top; width: 33.7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">(I.R.S. Employer</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Identification No.)</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 50.6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>300 East Main Street, Suite 201</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Charlottesville, Virginia</b></p>
			</td>
			<td style="vertical-align: bottom; width: 50.6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>22902</b></p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 50.6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">(Address of principal executive offices)</p>
			</td>
			<td style="vertical-align: top; width: 50.6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">(Zip Code)</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(434) 220-0718</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Registrant&#8217;s telephone number, including area code)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Not applicable</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Former name or former address, if changed since last report)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">&#9744;&nbsp; Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">&#9746;&nbsp; Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">&#9744;&nbsp; Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">&#9744;&nbsp; Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt; border-width: 1px; border-style: solid; border-color: black;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 42.8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 9pt;">Title of each class</p>
			</td>
			<td style="vertical-align: top; width: 24.6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 9pt;">Trading Symbol(s)</p>
			</td>
			<td style="vertical-align: top; width: 33.7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 9pt;">Name of each exchange on which registered</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 42.8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-right: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 9pt;">Common Stock, par value $0.001 per share</p>
			</td>
			<td style="vertical-align: top; width: 24.6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-right: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 9pt;">DFFN</p>
			</td>
			<td style="vertical-align: top; width: 33.7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 9pt;">NASDAQ Capital Market</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (</b>&#167;&#8201;<b>230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (</b>&#167;&#8201;<b>240.12b-2 of this chapter).</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b>Emerging growth company</b>&nbsp;&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</b>&nbsp; &nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;text-indent:-72pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Item 5.02 </b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On November 13, 2022, Eric Francois resigned from the board of directors (the &#8220;Board&#8221;) of Diffusion Pharmaceuticals Inc. (the &#8220;Company&#8221;) and all committees and subcommittees thereof, effective as of December 16, 2022. Mr. Francois currently serves as a member of the Board&#8217;s Audit and Compensation Committees. Mr. Francois indicated that his decision to resign was a result of certain mandatory internal policies and procedures of his current employer following a return to his investment banking career in late 2021, and was not the result of any disagreement with the Company, the Company&#8217;s management or the Board.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Also on November 13, 2022, in accordance with and pursuant to Section 3.2 of the Company&#8217;s Bylaws, as amended, the Board resolved to reduce the number of directors on the Board from seven to six, effective simultaneous with, and contingent upon, the effectiveness of Mr. Francois&#8217; resignation from the Board.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 8.01 </b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Other Events</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On November 14, 2022, the Company issued a press release providing an update on the Company&#8217;s previously disclosed evaluation of potential strategic opportunities, its upcoming annual meeting of stockholders, and certain related matters. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Item</b>&nbsp;<b>9.01</b>&nbsp;&#8211;&nbsp;<b>Financial Statements and Exhibits</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>(d) Exhibits</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:58.2761437908497%;margin-left:0pt;margin-right:auto;">

		<tr>
			<td style="vertical-align: top; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Exhibit</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Number</b></p>
			</td>
			<td style="vertical-align: top; width: 95%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Description</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 5%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 95%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">99.1</p>
			</td>
			<td style="vertical-align: top; width: 95%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="ex_446828.htm" style="-sec-extract:exhibit;">Press Release, issued November 14, 2022</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 5%;">&nbsp;</td>
			<td style="vertical-align: top; width: 95%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">104</p>
			</td>
			<td style="vertical-align: top; width: 95%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SIGNATURES</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="text-indent: 0; width: 100%;font-family: 'Times New Roman', Times, serif; font-size: 10pt">

		<tr>
			<td valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0;">Dated: November 14, 2022</p>
			</td>
			<td colspan="2" valign="top" width="38%">
			<p style="margin-top: 0; margin-bottom: 0;"><b>DIFFUSION PHARMACEUTICALS INC.</b></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td align="left" nowrap="nowrap" valign="bottom" width="35%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td align="left" style="text-align: left;" valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="text-align: left" valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">By: </font></p>
			</td>
			<td align="left" nowrap="nowrap" style="BORDER-BOTTOM: #000000 1px solid" valign="top" width="35%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">/s/&nbsp;</font>William Elder<font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0;">Name:</p>
			</td>
			<td valign="top" width="35%">
			<p style="margin-top: 0px; margin-bottom: 0px; text-indent: 9pt;">William Elder<font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0;">Title:<font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin-top: 0px; margin-bottom: 0px; text-indent: 9pt;">General Counsel &amp; Corporate Secretary<font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex_446828.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html><head>
	<title>ex_446828.htm</title>

	<!-- Generated by ThunderDome Portal - 11/14/2022 2:49:47 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="margin: 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 99.1</b></font></p>

<p style="margin: 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<div><img alt="image02.jpg" src="image02.jpg"></div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Diffusion Pharmaceuticals Sees Significant Progress in its Strategic Review Process </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>Diffusion in Active Bidding Stage and Encouraged by Response to the Strategic Review Process </i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>Diffusion Board of Directors Rejects Woefully Inadequate, Unsolicited Offer for the Company by client of Investment Bank LifeSci Capital</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>LifeSci-affiliated Fund Commences Proxy Contest for Control of the Diffusion Board Following Rejection of Client</i>&#8217;<i>s Offer</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>Company</i>&nbsp;<i>Believes LifeSci</i>&nbsp;<i>Proxy Campaign</i>&nbsp;<i>is Attempt to Circumvent</i>&nbsp;<i>Strategic Review Process</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>Date of Diffusion</i>&#8217;<i>s 2022 Annual Meeting of Stockholders Set for December 30, 2022</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">CHARLOTTESVILLE, Va., November 14, 2022&#8212;Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (&#8220;Diffusion&#8221; or the &#8220;Company&#8221;), a biopharmaceutical company developing novel therapies that may enhance the body&#8217;s ability to deliver oxygen to areas where it is needed most, today provided an update on the Company&#8217;s previously announced review and evaluation of strategic opportunities and its 2022 annual meeting of stockholders (the &#8220;2022 Annual Meeting&#8221;) to be held on December 30, 2022.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Diffusion Aggressively Pursuing Clear Strategy to Deliver Superior Value for Stockholders Led by Board</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As announced on October 25, 2022, Diffusion&#8217;s Board of Directors (the &#8220;Board&#8221;) is conducting a thorough evaluation of a comprehensive range of strategic opportunities to enhance stockholder value, including a sale, merger, divestiture, recapitalization or other strategic transaction, expanding on the Company&#8217;s previously disclosed business development efforts.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company has made significant progress since publicly announcing the strategic review process less than three weeks ago, building upon efforts over the course of the past year to identify a potential strategic transaction that will enhance value for Diffusion stockholders in this period of challenging market conditions. Since the Company&#8217;s public announcement, its management team has conducted meetings with multiple parties representing a broad range of interests and diverse array of potential transactions. Working together with its financial advisor, Canaccord Genuity LLC, and legal advisor, Dechert LLP, Diffusion is evaluating each interested party and opportunity in an effort to identify the most compelling, value-enhancing transaction for all stockholders. This includes assessing the potential for both short- and long-term value through the continued development of high potential therapies using the extensive skills and industry experience of the Company&#8217;s Board and management team.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company continues to believe that its lead product candidate, TSC, has the potential to deliver benefits to patients, particularly as an adjuvant treatment to standard of care therapy for hypoxic solid tumors, like glioblastoma multiforme, as well as long-term value for stockholders. However, the Company believes it is in the interest of all Diffusion stockholders to seek a near-term opportunity to leverage both the Company&#8217;s cash position and the significant skills and experience of its team to allow for a more effective use of resources, unlock the potential for TSC and enhance value for all Diffusion stockholders.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div><img alt="image02.jpg" src="image02.jpg"></div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">While the Company cannot provide any assurance as to the ultimate outcome of this strategic review process, the Company reports that it is in the active bidding stage and very encouraged by the overall response to the announcement of the Strategic Review Process. The Company&#8217;s Board and management team are highly motivated to complete this process as soon as possible.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Board Rejects Woefully Inadequate, Unsolicited Offer for the Company; Affiliate of the Investment Bank Life Sci Capital Commences Proxy Contest for Control of the Diffusion Board</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Despite the Board&#8217;s ongoing efforts, a group of stockholders affiliated with LifeSci Capital (together with its affiliates and representatives, &#8220;LifeSci&#8221;), which holds itself out as a boutique investment bank focused on the life sciences industry, has embarked on a campaign to capture for itself the significant value and potential of the Company&#8217;s assets at the expense of other stockholders.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Beginning in the late spring of this year, LifeSci approached the Company about the possibility of pursuing unidentified potential transactions with unidentified counterparties but refused to enter into a customary non-disclosure agreement or identify the principals on whose behalf it was supposedly acting. Then, on October 16, 2022, a LifeSci representative presented the Diffusion Board with an unsolicited offer to purchase Diffusion purportedly on behalf of a LifeSci client.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Diffusion Board of Directors, after deliberation and in consultation with its advisors, and in the exercise of its fiduciary duty to protect the interests of all Company stockholders, rejected the offer as woefully inadequate. The Board did, however, encourage LifeSci to join the ongoing strategic review process. Rather than engaging in the competitive process designed to enhance value for all Diffusion stockholders, LifeSci once again refused to enter into the customary non-disclosure agreement signed by other participants in the process and instead went silent. Then, on November 7, 2022, LifeSci notified the Company that it plans to commence a proxy contest on its own behalf and nominate its own slate of directors for election the 2022 Annual Meeting, with the intention of requesting that stockholders vote to replace Diffusion&#8217;s highly skilled and experienced directors with nominees that the Company believes lack relevant industry expertise and possess inferior skillsets to the current Board members.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">While Diffusion remains open to engaging constructively with all Company stockholders, including LifeSci, the Company believes LifeSci is determined to pursue a costly and self-serving campaign, the effect of which could undermine the strategic review process, divert management&#8217;s attention from expeditiously completing that process and the Company&#8217;s TSC development activities, and ultimately destroy stockholder value. Nevertheless, the Diffusion Board intends to vigorously oppose this effort by LifeSci and to protect stockholder value.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>2022 Annual Meeting</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">To, among other things, afford the Company more time to devote to progressing the strategic review process in a manner best designed to enhance stockholder value, the Board has determined that Diffusion&#8217;s 2022 Annual Meeting of stockholders will be held on&nbsp;December 30, 2022, approximately, two weeks later than previously announced.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div><img alt="image02.jpg" src="image02.jpg"></div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>About Diffusion Pharmaceuticals Inc.</b></p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Diffusion Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapies to enhance the body&#8217;s ability to deliver oxygen to areas where it is needed most. Diffusion&#8217;s lead product candidate, TSC, is being investigated to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine&#8217;s most intractable and difficult-to-treat conditions, including hypoxic solid tumors like GBM. For more information, please visit us at&nbsp;<u>www.diffusionpharma.com</u>.</p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Forward-Looking Statements</b></p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">This press release includes express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including: the timing and potential outcome of the Company&#8217;s ongoing strategic alternative review process; the potential therapeutic value of TSC in cancer and non-cancer indications; anticipated timelines for the initiation, completion, and announcement of data from Study 200-208; the Company&#8217;s ongoing and planned clinical trials; the Company&#8217;s near-term strategic priorities with respect to the development of TSC and otherwise; and the Company&#8217;s anticipated cash runway. The Company may, in some cases, use terms such as &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;approximately,&#8221; or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Although the Company believes that it has a reasonable basis for each forward-looking statement contained herein, forward-looking statements by their nature involve risks and uncertainties, known and unknown, many of which are beyond the Company&#8217;s control and, as a result, the Company&#8217;s actual results could differ materially from those expressed or implied in any forward-looking statement. Particular risks and uncertainties include, among other things, those related to: the Company&#8217;s ongoing strategic alternative review process; the novelty of the Company&#8217;s Oxygenation Trials&#8217; design and endpoints, the relevance of trends observed in those studies to any indication, including hypoxic solid tumors, and the therapeutic value of TSC; the optimal doses and dosing regimens of TSC in connection with the potential treatment of GBM; the Company&#8217;s ability to design, initiate, enroll, execute, and complete its planned studies evaluating TSC, including Study 200-208; the likelihood and timing of regulatory approval of TSC, if any, for the treatment of solid tumors complicated by hypoxia or any other indication, or the nature of any feedback the Company may receive from the U.S. Food and Drug Administration or other regulatory bodies; the impact of global supply chain disruptions on the Company&#8217;s drug product manufacturing capabilities, clinical development program, and associated timelines; the Company&#8217;s ability to identify, evaluate and execute potential business development transactional opportunities, if any; the Company&#8217;s ability to protect and expand its intellectual property portfolio; the Company&#8217;s access to capital resources: general economic, political, business, industry, and market conditions, including the ongoing COVID-19 pandemic, inflationary pressures, and geopolitical conflicts; and the other factors discussed under the heading &#8220;Risk Factors&#8221; in the Company&#8217;s filings most recent Annual Report on Form 10-K and other filings with the U.S. Securities and Exchange Commission. Any forward-looking statements in this press release speak only as of the date hereof (or such earlier date as may be identified) and, except as required by applicable law, rule, or regulation, the Company undertakes no obligation to update any such statements after the date hereof.</p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div><img alt="image02.jpg" src="image02.jpg"></div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Contacts</b><br>
<br>
<u>Gladstone Place Partners</u></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Felipe Ucr&#243;s / Christina Stenson</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">212-230-5930</p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Tiberend Strategic Advisors, Inc.</u>&nbsp;<br>
Daniel Kontoh-Boateng/Jonathan Nugent<br>
<u>dboateng@tiberend.com</u><br>
<u>jnugent@tiberend.com</u></p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Important Additional Information Regarding Proxy Solicitation</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Diffusion intends to file a definitive proxy statement and associated WHITE proxy card with the U.S. Securities and Exchange Commission (the </b>&#8220;<b>SEC</b>&#8221;<b>) in connection with the solicitation of proxies for Diffusion</b>&#8217;<b>s 2022 Annual Meeting (the </b>&#8220;<b>Proxy Statement</b>&#8221;<b>). Stockholders as of the record date of November 1, 2022 are eligible to vote at the Annual Meeting. Diffusion, its directors and certain of its executive officers will be participants in the solicitation of proxies from stockholders in respect of the 2022 Annual Meeting. Information regarding the names of Diffusion</b>&#8217;<b>s directors and executive officers and their respective interests in Diffusion by security holdings or otherwise is set forth in Diffusion</b>&#8217;<b>s proxy statement for the 2021 Annual Meeting of Stockholders, filed with the SEC on April 30, 2021, and the Company</b>&#8217;<b>s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 18, 2022. To the extent holdings of such participants in Diffusion</b>&#8217;<b>s securities have changed since the amounts set forth in the 2021 proxy statement, such changes have been reflected on Statements of Change in Ownership on Form 4 or Annual Statement of Changes in Beneficial Ownership on Form 5 filed with the SEC. Details concerning the nominees of Diffusion</b>&#8217;<b>s Board of Directors for election at the 2022 Annual Meeting will be included in the Proxy Statement. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND STOCKHOLDERS OF THE COMPANY ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH OR FURNISHED TO THE SEC, INCLUDING THE COMPANY</b>&#8217;<b>S DEFINITIVE PROXY STATEMENT AND ACCOMPANYING WHITE PROXY CARD, AND ANY SUPPLEMENTS THERETO, WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and stockholders will be able to obtain a copy of the definitive Proxy Statement and other relevant documents filed by Diffusion with the SEC free of charge from the SEC</b>&#8217;<b>s website, www.sec.gov., or by directing a request by mail to Diffusion Pharmaceuticals Inc., Attention: Corporate Secretary, at 300 East Main Street, Suite 201, Charlottesville, Virginia 22902, via e-mail to proxyrequests@diffusionpharma.com, or by visiting the investor relations section of Diffusion</b>&#8217;<b>s website, investors.diffusionpharma.com.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image02.jpg
<TEXT>
begin 644 image02.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
M   *    &@    !'<F5E;G-H;W0 _]L 0P '!04&!00'!@4&" <'" H1"PH)
M"0H5#Q ,$1@5&AD8%1@7&QXG(1L=)1T7&"(N(B4H*2LL*QH@+S,O*C(G*BLJ
M_]L 0P$'" @*"0H4"PL4*AP8'"HJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ_\  $0@ @0$V P$B  (1 0,1 ?_$
M !\   $% 0$! 0$!           ! @,$!08'" D*"__$ +40  (! P,"! ,%
M!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A""-"L<$54M'P)#-B<H()
M"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T
M=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%
MQL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$!
M 0$! 0$        ! @,$!08'" D*"__$ +41  (! @0$ P0'!00$  $"=P !
M @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:
M)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#
MA(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3
MU-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P# 0 "$0,1 #\ ]X\^7_GJ
M_P#WT://E_YZO_WT:910 _SY?^>K_P#?1H\^7_GJ_P#WT:910 _SY?\ GJ__
M 'T://E_YZO_ -]&F44 /\^7_GJ__?1H\^7_ )ZO_P!]&F44 /\ /E_YZO\
M]]&CSY?^>K_]]&F44 /\^7_GJ_\ WT://E_YZO\ ]]&F44 /\^7_ )ZO_P!]
M&CSY?^>K_P#?1IE% #_/E_YZO_WT://E_P">K_\ ?1IE% #_ #Y?^>K_ /?1
MH\^7_GJ__?1IE% #_/E_YZO_ -]&CSY?^>K_ /?1IE% #_/E_P">K_\ ?1H\
M^7_GJ_\ WT:910 _SY?^>K_]]&CSY?\ GJ__ 'T:910 _P ^7_GJ_P#WT://
ME_YZO_WT:910 _SY?^>K_P#?1H\^7_GJ_P#WT:910 _SY?\ GJ__ 'T://E_
MYZO_ -]&F44 /\^7_GJ__?1H\^7_ )ZO_P!]&F44 /\ /E_YZO\ ]]&CSY?^
M>K_]]&F44 /\^7_GJ_\ WT://E_YZO\ ]]&F44 /\^7_ )ZO_P!]&CSY?^>K
M_P#?1IE% %VPD=YV#NS#;T)SW%%,T[_CX;_<_J** *M%%% !1110 444W<OJ
M/SH =129STI: "BBL^[US3K&X\BYNE23NH!./KCI0!H44V.1)8U>-@R,,A@<
M@BFS31P1-).ZQHO5F. * )**Q'\6Z0DFW[0S?[0C.*UX9DN($FB.Y)%#*<=0
M: )**S+WQ!IMA(8Y[D&0=40%B/RJ73M8L]5W_8Y"QCQN!4C&: +U%%% !111
M0 4444 %%%9LFOZ7'=_9GNT$F<'@X!^O2@#2HI,YZ4M !1110 4444 %%%%
M!1110 4444 %%%% %K3O^/AO]S^HHHT[_CX;_<_J** *M%%% !1110!P'B^X
MF777197"!%PNXXZ>E9MIINI7T7FVL,DB9QN'3-7O&'_(PR?[B_RKH_!?_( _
M[;-_(4#.-ECU33'!D%Q;GLV2N?QK:T;QA/%*L.IGS8B<>;CYE^OK7:30QW$+
M13HKHPP58<&O,M;T\:9JTULOW <IGT/(H ]/5@ZAD(*L,@CN*\]UG0M2&L3L
MEO),LLA9749!!.:Z7P?>-<Z+Y;G)@;8"?3J*RM3\6ZA9ZG<6\20%(W*KN0YQ
M^= '1Z%9S6&BV]O<',B@DC/3))Q^M<IXRU%YM2^QJQ$4(&5'=B,YKH)-8N4\
M)#4@(_/*@XP=OWL=,UP5]>27]Y)<SA0\AR0HP* -71_"]QJUJ;GSEACR0N1D
MMBNHUFY?1?#")&^)0BPJP]<<D?@#7*6'BB^TZR2U@2$QIG!923R<^M1ZIXAO
M-7MUANEB"J^\;%(.<$>OO0!5TZPGU6_6WAQO;DLW0#U-=UX?T%]%:??,LOFA
M<$+C&,_XUPVF:G/I5T;BV"%RI7YQD8_R*[;3]:N;KPS<:A(L?G1[MH .W@ ^
MM &]17#VGC'49[V&%TM]KR*IPAZ$X]:[B@045PDOC/4DN'0);X5B!\A]?K7:
MVTQELH9I, O&&;T&1F@":BN-U7QI*)VBTM$"*<>:XR6^@K/3Q?JZ,"SHX]&C
M&#^6* /0'!9&4'!(QGTKS63P]JB7IA^RR,=W#@?*??->B6,TEQ8033($>1 Q
M4=LBN+;QIJ8D*A+?&<?</^- ':V4+6]C!#(VYXXU5F]2!4]1V[F6VBD;JR!C
MCW%9]]K"V[F. !W'!)Z"DY)+4UITIU9<L$:E%<W_ &S>==P'MM%7;+6A(XCN
M@%)Z,.E0JD6SIG@:T(WW->BBBM#A"BBN&G\9:C#>21[+?:CE?N'. ?K0!W-%
M<9JOC.43&+2PH1>#*PR6^@JM8^-+Z*<?;0D\1/S84*P^F* .\HJ.":.YMTFA
M;<DBAE/J*DH **** +6G?\?#?[G]111IW_'PW^Y_444 5:*** "BBB@#SSQA
M_P C#)_N+_*NC\%_\@#_ +;-_(5SGC#_ )&&3_<7^5=%X+/_ !(3_P!=F_D*
M!G0UY]XS8'7R!U6)0?\ /XUV6HZQ9Z9"SW$JEL?+&IRS'Z5YM>W<NHW\EQ(,
MO*V<#MZ"@#KO JD6-RW8R ?I_P#7KF=>_P"0]>?]=6_G7>>'M/.FZ-%%(,2M
M\[^Q/;\L5P>O?\AZ\_ZZM_.@#NM"ACG\,VL<\:R(R<JXR#S7#^(8HX->N8X4
M6-%8851@#@5W?AS_ )%ZT_W/ZFN'\3?\C%=_[P_D* .I\,Z;97'A^WDGM()'
M);+/&"3\Q[U4\8V%I:Z5"]M;0PL9@"40 D;3Z5J>%/\ D6K;ZM_Z$:I>.?\
MD#P?]=Q_Z":!&%X1MX;G6F2YB25/*8[74$9R/6NPU2WAMO#]Y';Q)$GE,=J*
M ,XKD_!7_(=;_KBW\Q79:NA?1;Q5ZF%OY4 >:Z=_R%;7_KLG_H0KU>O)+640
M7L,K=(Y Q_ UZH][;I9_:FF3R=N[?G@B@9Y7<?\ '[)_UT/\Z]),<DOAD1P_
MZQK4!?KMKS61Q)<LXZ,Y/ZUZEIY TNV). (5R3]* /+H9/L]XDDD8?RW!9&[
MX/0UWMGKFC:L@AE2-&;CRYD&/P/2GZEX9L-58SH3#*W/F1\AO<CO7#ZMIKZ3
MJ#6TCJY #!E[@T >I !5"J, # %>1O\ Z]O][^M>A^%KN6[T&,S$LT;%-QZD
M#I_.O/'_ ->W^]_6@#U RF#14D!P1"N#[X%<[;QFXND3^^P!K?EC,N@JHZ^4
MI_( UA6DOD7D;MT5AGZ5A4^)'L8#^#)QW_X!U MH5A\H1KLQC&*Y>\A^SWDD
M:]%;CZ5U@8%=P(QC.:Y6_E$]]*Z<@MQ[TZMK$9=*;G*^QT&F3&;3XV;J.#^%
M6JSK."4:*$B;9(PR#^-5I]*GC@:;[26=1DCG^=5S-):',Z5.=25Y6U-NO)[_
M /Y"5S_UU;^=>CZ/=27%NZRG<T9ZGT_R*\XO_P#D)7'_ %U;^=6G=7.:I3=.
M;@^AW&@Z#8+H\,D]M'-),@=FD7.,]AZ5R&O6*:=K4]O#Q&""H] 1G'ZUZ%H_
M_($L_P#KBO\ *N'\7_\ (QS?[J?^@BF0=3X1D:3P_&&.=CLH^G7^M;E8'@[_
M )  _P"NC?TK?H$%%%% %K3O^/AO]S^HHHT[_CX;_<_J** *M%%% !1110!Q
M'BC2+^ZUEYK>VDDC*J RC/:L=-(U9/E2TN![!37I]% 'G$/A?5[E_FMS'_M2
M-C_Z]=-HOA2#39%GN6$\Z_=X^53[>M=#10 5Y_J^@ZE<:Q<RPVCLCR$J1W%>
M@44 9^AP26VBVT,ZE)$7#*>W-<GKVAZC=:Y<S6]J[QLPPP[\5WE% &7X<MIK
M30H(;E#'(I;*GM\QJKXML;F_TR*.TB:5UF#$#TP:WJ* .-\*Z1?6.KF6ZMVC
M3RB-Q]<BNQ8!E*L,@C!![TM% 'GFK>%[RSNG-K"T]N3E"@R0/0BH;'P]JEZZ
MQF%X8L\M*" /P[UZ310!YW?>&+^&^D2TMI)85/ROQS79/!<GPWY$2XN#;A I
M.,'&*TJ* /-Q9Z_8';$EW'[1EL?I2P>']7U*XW312*6/S2SDC^?->CT4 5--
ML(],T^.UBY"#EO[Q[FN ;P[JIF)^QR8W9KTJB@"*V4I:1(XP1&H(_"LB^T9Q
M(9+094\[.X^E;E%3**EN;T:\Z,KQ.7\B_"^4%FV_W><5:LM&D9P]T-J#^'N:
MWJ*A4UU.F>/J-6BDA  !@< 5EZI?9S:6WSR-PV.WM5V]6=K5EM>'/'7'%8\.
MG:A!(7B 5CQG(IS;V1.%A3_B3DKK9,U-.L_L=MM;[['+?X5PMYX?U22^G=+-
MRK2,0?49KN+!+U6?[:V1@;>1_2KU5'8YZU_:-MW]"IID3PZ3:Q2KM=(E5@>Q
MQ7)^)=&U"]UR6:VMGDC*J P[\"NWHJC$Q_#%I/9:,(KJ,QR>83M/X5L444 %
M%%% %K3O^/AO]S^HHHT[_CX;_<_J** *M%%% !1110 UY$B7=(ZH/5CBFQSQ
M39\F5),==K USWC.-98-,CD4,CWT:L#W!S5;Q+I-CI&FC4-,06=W#(OEF,D;
M\GD8[\<_A0!T\EY;Q7<=M)*JS2@E$/5@*GKDM:O$M?%.CW-UE0(&+ #)R1T
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M.L@%OS%(KD.OXTD'AS3[>ZAND21KB%BPE>0LS$C')/6@"EIW_(^:O_URB_\
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M73W"":WDD.7\B0H&^H%2MH%@YLRR.?L1_=?.?7//K0!IT444 %%%% %K3O\
MCX;_ '/ZBBC3O^/AO]S^HHH JT444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 6M._X^&_W/ZBBC3O\ CX;_ '/ZBB@"K1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
<0 4444 %%%% !1110!:T[_CX;_<_J**** /_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
